search
Back to results

Intravitreal Bevacizumab for Diabetic Macular Edema

Primary Purpose

Macular Edema, Diabetic Retinopathy

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Bevacizumab
Sponsored by
Isfahan Ophthalmology Research Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional trial for Macular Edema

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diabetes mellitus
  • Clinically significant macular edema
  • Possibility of performing macular OCT
  • Consent of patient for inclusion in the study

Exclusion Criteria:

  • History of macular photocoagulation in less than 6 months of inclusion in the study
  • Necessity of surgical intervention
  • Rejection of the remaining in the study by patient

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    June 20, 2008
    Last Updated
    June 20, 2008
    Sponsor
    Isfahan Ophthalmology Research Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00703235
    Brief Title
    Intravitreal Bevacizumab for Diabetic Macular Edema
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2008
    Overall Recruitment Status
    Unknown status
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Isfahan Ophthalmology Research Center

    4. Oversight

    5. Study Description

    Brief Summary
    Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Macular Edema, Diabetic Retinopathy

    7. Study Design

    Study Phase
    Phase 2, Phase 3

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Bevacizumab

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diabetes mellitus Clinically significant macular edema Possibility of performing macular OCT Consent of patient for inclusion in the study Exclusion Criteria: History of macular photocoagulation in less than 6 months of inclusion in the study Necessity of surgical intervention Rejection of the remaining in the study by patient

    12. IPD Sharing Statement

    Learn more about this trial

    Intravitreal Bevacizumab for Diabetic Macular Edema

    We'll reach out to this number within 24 hrs